Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors [0.03%]
酪氨酸激酶抑制剂治疗的表皮生长因子受体突变型非小细胞肺癌患者的中性粒细胞/淋巴细胞比值的影响
Taihei Ono,Satoshi Igawa,Shintaro Kurahayashi et al.
Taihei Ono et al.
Background Exon 19 deletion and L858R point mutation in exon 21 of the epidermal growth factor receptor (EGFR) are the most commonly encountered mutations in patients with non-small cell lung cancer (NSCLC) and predict better clinical outco...
Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer [0.03%]
二甲双胍联合卡铂和紫杉醇新辅助化疗治疗晚期卵巢癌患者I期临床研究
K Esther Broekman,Marieke A J Hof,Daan J Touw et al.
K Esther Broekman et al.
Background Metformin use is associated with reduced cancer risk in epidemiological studies and has preclinical anti-cancer activity in ovarian cancer models. The primary objective of this phase I study was to determine the recommended phase...
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma [0.03%]
一项关于小分子转化生长因子-β受体I抑制剂galunisertib与标准替莫唑胺为基础的放化疗联合治疗新诊断恶性胶质瘤患者的Ⅰb/Ⅱa期临床研究
Antje Wick,Annick Desjardins,Cristina Suarez et al.
Antje Wick et al.
Purpose Galunisertib, a TGF-β inhibitor, has demonstrated antitumor effects in preclinical and radiographic responses in some patients with malignant glioma. This Phase 1b/2a trial investigated the clinical benefit of combining galuniserti...
Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer [0.03%]
放疗联合度伐利尤单抗治疗局部晚期非小细胞肺癌后放射性肺炎的相关临床和剂量体积因素
Hiroto Inoue,Akira Ono,Takanori Kawabata et al.
Hiroto Inoue et al.
Introduction Durvalumab has been shown to confer a survival benefit after definitive chemoradiotherapy in the patients with locally advanced non-small cell lung cancer, but no studies have attempted to identify risk factors for pneumonitis ...
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma [0.03%]
复发和/或难治性多发性骨髓瘤患者中蛋白脱泛素酶抑制剂VLX1570 I期临床研究
Eric K Rowinsky,Agne Paner,Jesus G Berdeja et al.
Eric K Rowinsky et al.
This phase 1 study sought to characterize the safety, tolerability, and pharmacokinetic behavior of VLX1570, a small molecule inhibitor of the deubiquitinases (DUBs) that remove sterically bulky ubiquitin chains from proteins during process...
Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma [0.03%]
阿帕替尼和安罗替尼治疗晚期骨及软组织肉瘤患者疗效与安全性回顾性分析
Zhichao Tian,Huimin Liu,Fan Zhang et al.
Zhichao Tian et al.
Background Previous studies have demonstrated the efficacy of apatinib and anlotinib for the treatment of sarcomas. However, more clinical data and evidence are needed to support clinical treatment selection and study design. Here, we evalu...
Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study [0.03%]
帕博利珠单抗与高剂量干扰素α-2b作为中国III期黑色素瘤术后患者辅助治疗的回顾性队列研究
Tao Li,Dong-Dong Jia,Li-Song Teng
Tao Li
Background Pembrolizumab has robust antitumor activity in advanced melanoma and has been approved for the treatment of melanoma in many countries. Adjuvant pembrolizumab was associated with longer recurrence-free survival (RFS) in patients ...
Anticancer activity of Turkish marine extracts: a purple sponge extract induces apoptosis with multitarget kinase inhibition activity [0.03%]
土耳其海洋提取物的抗癌作用：一种紫色海绵提取物通过多靶点激酶抑制活性诱导凋亡
Halil I Ciftci,Mustafa Can,Doha E Ellakwa et al.
Halil I Ciftci et al.
Marine natural products have drawn a great deal of attention as a vital source of new drugs for the last five decades. However, marine organisms in the seas surrounding Turkey (the Black Sea, the Aegean Sea and the Mediterranean Sea) haven'...
Evaluating the antitumor activity of sphingosine-1-phosphate against human triple-negative breast cancer cells with basal-like morphology [0.03%]
评估鞘氨醇-1-磷酸对具有基底样形态的人三阴性乳腺癌细胞的抗肿瘤活性
Omar Abuhussein,Jian Yang
Omar Abuhussein
Sphingosine-1-phosphate (S1P) is an important sphingolipid metabolite that regulates a wide range of physiological and pathophysiological processes. Our previous studies show that S1P selectively induces cell apoptosis in human breast cance...
Combating atherosclerosis with targeted Diosmin nanoparticles-treated experimental diabetes [0.03%]
用靶向迪奥斯明纳米颗粒治疗糖尿病以对抗动脉粥样硬化
Hendawy Om,Mehrez E El-Naggar,Mona El-Banna et al.
Hendawy Om et al.
Diabetes with poor glycemic control is accompanying with an increased risk of disease namely atherosclerotic cardiovascular. Diosmin (DSN), which is obtained from citrus fruit used to assist the treatment of hemorrhoids or chronic venous at...